PERIPHERAL T-CELL LYMPHOMA

This program provides early access to the investigational drug selinexor for people with multiple myeloma, lymphoma, sarcoma, or other cancers who have exhausted all approved treatments and cannot join a clinical trial. Patients must get approval from their doctor and local healt…

This early-stage study tests a new type of cell therapy for people with certain lymphomas that have come back or not responded to treatment. The therapy uses immune cells from healthy donors that are modified to better recognize and attack cancer cells, plus an added molecule to …

This study tests a combination of two drugs, sintilimab and chidamide, in people with a rare blood cancer called peripheral T-cell lymphoma that has returned or not responded to prior therapy. The goal is to see if this combination can control the cancer longer. About 51 adults a…

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard chemotherapy. It compares two approaches: a donor stem cell transplant (allogeneic HSCT) or other rescue treatments. The goal is to see which option helps patients liv…

This study is testing a new type of CAR-T cell therapy that targets two different markers on cancer cells at the same time. It is for adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The goal is to se…

This phase 3 study tests whether adding the drugs Beleodaq or Folotyn to standard chemotherapy (CHOP) helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three trea…

This study looks at people with peripheral T-cell lymphoma whose cancer went away after their first treatment. It compares two options: getting a stem cell transplant using their own cells, or simply watching and waiting. The goal is to see which approach helps keep the cancer aw…

This study tests whether two drugs, cidabenamine and azacitidine, can keep high-risk peripheral T-cell lymphoma from returning after a stem cell transplant. About 40 adults aged 18 to 70 will receive this maintenance therapy. The goal is to see if the combination improves surviva…

This study tests a new treatment for people with a rare type of blood cancer (peripheral T-cell lymphoma) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer ce…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…

This study tests whether adding the experimental drug lacutamab to standard chemotherapy helps people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to previous treatments. About 56 adults whose cancer cells have a specific m…

This early-stage trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the i…

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with a type of blood cancer (peripheral T-cell lymphoma) that has come back or stopped responding to treatment. About 101 adults will take p…

This early-phase trial tests a new drug called ST-001 in people with T-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to find the safest dose and to watch for side effects. About 46 participants will receive the drug through a…

This study tests whether the drug golidocitinib, given alone or with standard chemotherapy (CHOP), can help control peripheral T cell lymphoma (PTCL) in newly diagnosed patients. About 30 adults will take part to see if the treatment is safe and effective. The goal is to manage t…

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not improved after at least one prior therapy. About 218 participants will be randomly assigned to receive either gol…

This study looks at two types of stem cell transplants for people with a rare blood cancer called peripheral T-cell lymphoma that only partially improved after initial treatment. One group receives their own stem cells, while the other gets stem cells from a healthy donor. The go…

This study tests whether a daily pill called golidocitinib can help keep peripheral T-cell lymphoma from coming back after successful first chemotherapy. About 136 adults who responded to initial treatment but cannot have a stem cell transplant will receive either the study drug …

This study tests whether adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combina…

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy for people with peripheral T-cell lymphoma, a rare blood cancer. The trial involves about 134 adults aged 18-80. The goal is to see if the new combo works better at …

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…

This study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…

This study tests an experimental drug called HH2853 for people with certain types of blood cancer (non-Hodgkin's lymphoma) or advanced solid tumors that have come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. About …

This study will follow about 3,000 people in China with peripheral T-cell lymphoma, a rare blood cancer. Researchers will look at how the disease is treated in everyday practice, what genetic changes occur, and how long patients live. The goal is to learn more about the disease a…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. T…